Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

Merck & Co – known as MSD outside of the US and Canada – has shared positive results from a late-stage trial of a Keytruda (pembrolizumab)/Lynparza (olaparib) regimen as a first-line treatment for ...

Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) as a treatment for adults ...

Gilead Sciences has appointed Dietmar Berger as chief medical officer and a member of its senior leadership team. Berger, who will assume the role at the beginning of 2025, is a board-certified ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a ...

Iona Everson from PMGroup spoke to John Forni, Country Medical Director at Sanofi UK & Ireland, about the escalating challenges of treating chronic obstructive pulmonary disease (COPD) in the UK and ...

The National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ Agamree (vamorolone) to treat Duchenne muscular dystrophy (DMD). The drug has been recommended ...

Amgen’s Blincyto (blinatumomab) has been granted a licence extension by the Medicines and Healthcare products Regulatory Agency (MHRA) in acute lymphoblastic leukaemia (ALL). The immunotherapy has ...

Global strategic partner in healthcare, Avalere Health, is proud to announce the appointment of Amar Urhekar as its new Chief Executive Officer. Urhekar joined Avalere Health in 2023 as Chief ...